The Henrietta Lacks Settlement: A Historic Step Toward Justice

A Landmark Agreement Decades in the Making

Novartis, one of the world’s most powerful pharmaceutical companies, has reached a settlement with the estate of Henrietta Lacks, closing a painful chapter in a story that spans more than seven decades. The lawsuit centered on cells taken from Lacks’ body without her consent in 1951—cells that would go on to revolutionize modern medicine and generate untold billions in profits for the biomedical industry. While the specific terms of the agreement remain confidential, both parties expressed satisfaction that they could resolve the matter outside of court. This settlement represents the second major victory for the Lacks family, following a 2023 agreement with biotechnology giant Thermo Fisher Scientific. For the descendants of a woman who died in poverty and was buried in an unmarked grave, these settlements acknowledge a fundamental injustice: that the medical establishment built fortunes on the tissue of a Black woman whose family never received a penny, and whose consent was never sought.

The case highlights a broader reckoning with how the medical community has historically exploited marginalized patients, particularly African Americans. Henrietta Lacks was just 31 years old when cervical cancer took her life, leaving behind five children and a husband struggling to make ends meet. She could never have imagined that cells from her body would become one of the most important tools in medical research, contributing to breakthroughs including the polio vaccine, genetic mapping, cancer treatments, and even COVID-19 vaccines. The legal actions taken by her estate don’t just seek financial compensation—they demand recognition of a system that devalued Black lives and bodies, treating them as resources to be harvested rather than people deserving of dignity, respect, and informed consent.

The Stolen Cells That Changed Medicine Forever

Henrietta Lacks’ story begins in the tobacco fields of southern Virginia, where she was born into poverty. She eventually married and moved with her husband to Turner Station, a historically Black community just outside Baltimore, Maryland, where they were raising five children when tragedy struck. In 1951, doctors at Johns Hopkins Hospital discovered a malignant tumor on her cervix. During her biopsy, physicians took a sample of her cancer cells—a routine practice at the time, but one done without her knowledge or permission. What happened next would transform medical science forever, though Lacks herself would not live to see it.

Unlike typical cell samples, which died shortly after being removed from the human body, Henrietta’s cells proved extraordinary. They survived, multiplied, and thrived in laboratory conditions in ways that baffled and excited researchers. Scientists named them “HeLa” cells, using the first two letters of her first and last names, and they became the first “immortalized” human cell line—meaning they could reproduce indefinitely outside the body. This characteristic made them invaluable to researchers worldwide, who could now conduct experiments using identical cells, ensuring consistency and reproducibility in their studies. These cells were shipped to laboratories across the globe, becoming the foundation for countless medical breakthroughs that have saved millions of lives.

The scientific contributions of HeLa cells cannot be overstated. They were instrumental in developing the polio vaccine, which eradicated one of the most feared diseases of the 20th century. Researchers used them to advance our understanding of cancer, AIDS, the effects of radiation and toxic substances, and gene mapping. More recently, they played a role in developing COVID-19 vaccines that have protected billions of people worldwide. Yet while these cells generated immeasurable value—both in terms of human health and corporate profits—Henrietta Lacks’ family struggled with poverty, chronic illnesses, and lack of access to the very healthcare system that had enriched itself through her biological legacy.

The Family Left Behind and a Racist Medical System

While Novartis and countless other companies built profitable enterprises using HeLa cells, the Lacks family faced their own health crises without the resources to address them. Some family members suffered from chronic illnesses but had no health insurance, creating a bitter irony: the cells that came from their mother and grandmother were healing the world, yet they couldn’t afford basic medical care. This stark disparity illustrates the deep injustices embedded in a medical system that historically viewed Black patients as subjects for experimentation and exploitation rather than as people deserving care and respect.

Johns Hopkins Hospital, where Henrietta’s cells were originally taken, has maintained that it never sold or profited directly from the HeLa cell line. However, this defense misses the broader point of the family’s grievance. While the hospital itself may not have commercialized the cells, it operated within and perpetuated a system that took biological material from vulnerable patients without consent, enabling countless private companies to build lucrative businesses. Many corporations have patented specific applications and uses of HeLa cells, turning them into proprietary products that generate substantial revenues. The Lacks family’s lawsuits argue that this constitutes unjust enrichment—these companies grew wealthy from cells that were, in the most fundamental sense, stolen property.

The lawsuit against Novartis specifically sought “the full amount of its net profits obtained by commercializing the HeLa cell line.” This bold demand reflects the family’s position that partial compensation or token gestures are insufficient. For decades, the biomedical industry benefited from a racial hierarchy that deemed Black bodies available for medical use without the protections of informed consent afforded to white patients. The Lacks family’s legal strategy represents not just a pursuit of financial justice for their specific case, but a challenge to the entire framework that allowed such exploitation to occur and continue even after Henrietta’s story became widely known.

Bringing Henrietta’s Story to the World

For many years, the story of Henrietta Lacks and her miraculous cells remained largely unknown outside scientific circles, and even within those circles, few considered the ethical implications or the family left behind. That changed dramatically in 2010 when journalist Rebecca Skloot published “The Immortal Life of Henrietta Lacks,” a deeply researched and compassionate book that told both the scientific story of the cells and the human story of the family. The book became a bestseller, introducing millions of readers to Henrietta’s legacy and the profound ethical questions surrounding her case.

The impact of Skloot’s work extended beyond the page. In 2017, HBO adapted the book into a film starring Oprah Winfrey as Henrietta’s daughter, Deborah Lacks, bringing the story to an even wider audience. These cultural works transformed Henrietta from a footnote in medical history—a set of initials on a petri dish—into a fully realized person whose life, death, and unwitting contribution to science raised urgent questions about consent, exploitation, racism in medicine, and who has the right to profit from human biological material. The visibility created by the book and film also provided crucial support for the family’s legal efforts, generating public sympathy and putting pressure on companies that had long operated in comfortable anonymity.

Ongoing Legal Battles and the Path Forward

The settlement with Novartis doesn’t close the book on the Lacks family’s pursuit of justice. Lawsuits against other pharmaceutical companies, including Ultragenyx Pharmaceutical and Viatris, remain active in federal court. Attorneys representing the estate have indicated that additional complaints may be filed against other companies that have profited from HeLa cells. This multipronged legal strategy suggests the family’s commitment to holding the entire industry accountable, not just securing settlements from individual companies.

Each settlement and ongoing lawsuit serves multiple purposes. On a practical level, they seek financial compensation for a family that was excluded from the wealth generated by their ancestor’s cells. On a moral level, they demand acknowledgment of wrongdoing and a fundamental shift in how the biomedical industry approaches questions of consent, compensation, and the rights of patients and their descendants. The cases also set important legal precedents that could affect how courts view the commercialization of human biological materials more broadly, potentially offering protections to other families and individuals whose tissues have been used in research and product development without their knowledge or consent.

The Lacks family’s legal actions come at a time of broader reckoning with medical racism and ethical violations in research. From the infamous Tuskegee syphilis study to more recent revelations about bias in medical algorithms and treatment, the healthcare system is being forced to confront its history of devaluing and exploiting Black patients. The Lacks settlements represent tangible accountability—not just symbolic gestures, but actual transfer of wealth from corporations that profited from injustice back to the family that bore its costs. While no amount of money can truly compensate for what was taken from Henrietta Lacks or restore the decades her family spent in poverty while companies grew rich, these settlements represent an important acknowledgment: that Black lives have value, that consent matters, and that profiting from exploitation—even historical exploitation—demands accountability and restitution. As the remaining lawsuits proceed and potentially new ones are filed, the Lacks family continues to advocate not just for themselves, but for a more just and equitable medical system for everyone.